Themis Medicare LtdQ3 FY23Pharmaceuticals & Biotechnology

Themis Medicare Ltd

Q3 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→The hospital segment is expected to see significantly higher growth in the second half of the year compared to the first half, driven by de-bottlenecking and improved supply capabilities.
→New product launches, such as Remithem, are anticipated to boost sales and expand market presence, especially in hospitals.
→The domestic hospital and trade (branded) businesses contributed notably to recent growth, with trade domestic business growing 35-40%.
→Growth is expected to sustain and improve in the domestic market as the company leverages its established distribution network and expands product offerings.
→Marketing investments aim to increase doctor touchpoints and product portfolio in hospitals without increasing fixed costs, focusing on productivity over headcount growth.
→The company foresees no major capacity expansion capex soon, relying on contract manufacturing to meet rising demand.
→Long-term strategy includes expanding into women’s healthcare and other hospital specialties for diversified growth.

Category 1

→Hospital segment expected to experience significantly higher growth in the second half of FY ’24 due to resolved supply constraints and new product launches (e.g., Remithem).
→Strong focus on increasing hospital product basket and doctor touchpoints to drive revenue without significantly increasing fixed costs.
→EBITDA margin pressure due to raw material price increases (API costs) and manpower additions in hospital business; improvements expected as new API manufacturing routes are adopted and operational productivity rises.
→Long-term strategy includes investing more in marketing, which may temporarily depress margins but should drive top-line growth.
→API business transfer to a subsidiary to streamline focus and growth expected to benefit overall financials.
→EPS showed growth with H1 FY ’24 EPS at INR32.07 and quarter EPS at INR12.30, expected to improve with margin recovery and revenue growth.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Themis Medicare Ltd and 1,400+ other companies.

→There is no specific mention of any current or planned new fundraising through debt or equity in the call transcript.
→The company stated that they have not planned any capital expenditure (capex) for capacity expansion in the next few years, indicating no immediate need for fundraising for expansion.
→The API business is being transferred to a wholly-owned subsidiary to focus and streamline growth; no fundraising related to this is indicated.
→The company emphasized reliance on contract manufacturing to meet demand instead of investing in new manufacturing capacity.
→They are focusing on improving productivity and marketing within existing resources.
→No explicit plans for issuing new equity or raising debt were discussed during this period.

→The transcript does not specifically mention the current or expected order book or pending orders for Themis Medicare Limited.
→However, it highlights a strong momentum in the hospital segment with 20% growth in Q2 FY’24 and expectations of even higher growth ahead.
→The company has completed de-bottlenecking to meet demand, implying a readiness to fulfill existing and future orders.
→Multiple new product launches, including Remithem (Remifentanil) and others, are expected to boost hospital business growth.
→Investments in expanding the hospital team and marketing efforts signal increasing capacity to handle more orders.
→Contract manufacturing partnerships indicate preparation to meet rising demand without capex expansion.
→Overall, while exact orderbook numbers aren't given, the company is positioned for a robust increase in order flow and execution going forward.

→No significant planned capex for capacity expansion over the next few years; current production can be met through contract manufacturing facilities.
→Investment focus is on increasing productivity and marketing efforts rather than expanding manpower or fixed capacity.
→The company has set up a small R&D unit in Gujarat (Baroda) to work on certain molecules not permitted in existing facilities; this is not a manufacturing unit.
→Strategic investment is focused on expanding product offerings in hospital business, leveraging existing distribution networks.
→Capital allocation is more towards varied marketing expenditure to promote new products, especially in hospital and trade segments.
→The transfer of API business to a wholly-owned subsidiary aims at enabling focused growth and capital efficiency but does not involve new capital expenditure.
→Overall, growth strategy prioritizes variable marketing and R&D investments over fixed capital spending.

How does Themis Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Themis Medicare Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Themis Medicare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.